drugset / Trial / NCT01632605
The Vienna RAP Pilot Study
NaSingle-groupOpen-label
Summary
The purpose of this study is to evaluate the safety of a daily single oral dose of sirolimus in patients with advanced autosomal dominant polycystic kidney disease.
Timeline
- Start
- 2009-11
- Primary completion
- 2012-04
- Completion
- 2012-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sirolimus | Small molecule | 1 mg | Oral |
| Subject | Sirolimus | Small molecule | 3 mg | Oral |